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Bronchial hyperresponsiveness is present in 41X60% of adult patients with cystic fibrosis (CF). Drugs which 
alter airway hyperresponsiveness have not yet been studied in CF. In this randomized placebo-controlled 
study, we investigated the effects of an inhaled corticosteroid, budesonide, on lung function and bronchial 
hyperresponsiveness in adult CF patients, with proven bronchial hyperresponsiveness to histamine. Twelve 
patients were treated with budesonide, 1600 ,ug day - i, and with placebo during two periods of 6 weeks in a 
randomized, double-blind, cross-over study. Drug effects were assessed with regard to bronchial hyperrespon- 
siveness to histamine, spirometry and clinical symptom scores. After treatment with budesonide, no significant 
differences in spirometry were seen, however, bronchial hyperresponsiveness to histamine significantly 
improved as compared to baseline. Fifty-eight percent of the patients showed at least one doubling-dose 
increase in PC,, histamine. Daily symptom scores showed small, but statistically significant, improvements in 
dyspnoea and cough after budesonide treatment. There is increasing evidence suggesting that excessive 
inflammatory responses contribute to the pulmonary damage that characterizes CF. Treatment with oral 
corticosteroids improved the clinical course of selected CF patients, but was associated with unacceptable 
adverse effects. We conclude that daily inhalation of 1600 fig day - ’ budesonide for 6 weeks induced a small, 
but significant, improvement in bronchial hyperresponsiveness to histamine, and symptoms of cough and 
dyspnoea in adult CF patients. Longer observations are needed to establish whether inhaled corticosteroids 
improve the long term outcome of CF. 
Introduction 
Bronchial hyperresponsiveness is a functional 
characteristic of bronchial asthma. Its presence can 
be demonstrated by assessing the bronchoconstrictor 
response to inhaled pharmacologic agents, such as 
histamine and methacholine. Patients with cystic 
fibrosis (CF) show this hyperresponsiveness to 
inhaled stimulants in 4&60% of cases (14). The 
mechanism of bronchial hyperresponsiveness in CF is 
unclear, although a relation with the underlying 
airway disease has been suggested (2). Existing air- 
way narrowing and thickening of the airway wall 
may alter the airway geometry to such an extent, that 
a small increase in degree of narrowing produces a 
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greater relative change in cross-sectional area (5). In 
addition, chronic inflammation may enhance the 
mucosal permeability and allow better penetration of 
histamine to bronchial smooth muscles and ‘irritant’ 
receptors (6). However, observations that FEV, is 
lower in hyperresponsive CF patients (2,4,7) than in 
non-hyperresponsive CF patients, are not confirmed 
by other authors (3,8). Others have suggested that 
airway hyperresponsiveness in CF is a genetically 
determined, systemic abnormality, associated with 
abnormal autonomic responses (9,lO). Regardless of 
its cause, bronchial hyperresponsiveness in CF 
appears to be an unfavourable prognostic finding, as 
demonstrated in a prospective study in which the 
natural history of lung disease was more severe in 
hyperresponsive CF patients (2). In patients with 
allergic asthma, treatment with inhaled corticoster- 
oids induces a clear change in bronchial hyperrespon- 
siveness, expressed by increases in tolerance to 
histamine and ultrasonically nebulized distilled 
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water, improvement of lung function and clinical 
symptom scores (1 l-l 3). Drugs which alter airway 
hyperresponsiveness have not yet been studied in CF. 
In this randomized, placebo-controlled study, we 
investigated the effects of an inhaled corticosteroid, 
budesonide, on lung function and bronchial hyper- 
responsiveness in adult CF patients, with proven 
bronchial hyperresponsiveness to histamine. 
Subjects and Methods 
SUBJECTS 
Sixteen CF patients (mean age 27 years; range 
16-45 years) volunteered to participate in the study. 
The diagnosis CF was established by sweat test. All 
patients had a baseline FEV, above 25% of predicted 
values (14) absence of a recent (~6 weeks) acute 
pulmonary exacerbation and a PC,, FEV, histamine 
below 16 mg ml - i . Excluded were pregnant patients, 
patients who used oral corticosteroids or patients 
with severe concomitant disease which might inter- 
fere with the study and performing the tests. The 
study was approved by the hospital’s Medical Ethics 
Committee, and written informed consent was 
obtained from all subjects. 
METHODS 
The study consisted of three periods. Period one 
was a run-in period of 2 weeks and periods two and 
three were double-blind, placebo-controlled, cross- 
over medication periods of 6 weeks. At the first and 
last day of the run-in period, and at the last day of 
each treatment period, the patients underwent 
spirometry and a histamine provocation test. Inhaled 
bronchodilators were withheld for at least 12 h prior 
to each visit, while test medication was continued 
normally. Throughout the entire study, patients 
maintained a diary of symptoms and daily peak 
expiratory flow rate (PEFR) measurements. The best 
of three PEFR measurements was recorded twice 
daily, before medication use. On each day, scores for 
dyspnoea at rest and during exercise, cough and 
sputum production were recorded (O-3: O=no com- 
plaints, 3 = severe complaints). Only /&-agonists were 
allowed to be used as bronchodilators if necessary, 
and their use was recorded. Prophylactic antibiotics, 
pancreatic enzymes and vitamin supplements when 
appropriate, were continued throughout the trial. 
Sodium cromoglycate, antihistaminics and theophyl- 
line preparations were stopped prior to the study 
protocol. Lung function tests were performed with 
a standard wet spirometer (Pulmonet III, Sensor- 
Medics, Bilthoven, The Netherlands). Allergy status 
was checked by RAST tests for 10 common 
Table I Patient characteristics 
Patient 
no. sex 
Age FEV, 
(years) (“AI Pred) Allergy 
1 M 28 51 + 
2 M 23 24 + 
3 M 29 98 + 
4 M 21 32 - 
5 M 31 85 - 
6 M 26 55 - 
7 F 25 31 - 
8 F 29 75 - 
9 M 22 87 + 
IO M 16 78 - 
II F 24 41 
12 F 34 50 - 
Mean 26 59 - 
SEM 2 I - 
inhalational allergens. Allergy was defined as at 
least one positive test result by the RAST method. 
Standardized histamine provocation tests were 
performed, and computerized calculations of the 
provocative concentration of histamine producing 
a 20% fall in FEV, (PC,, histamine) were made (15). 
A pulmonary exacerbation of CF (defined as fever, 
increase in coughing and sputum production, weight 
loss, decrease in lung function and the need for 
antibiotic intervention) was reason for removal from 
the trial. Blinded, metered dose inhalers were 
supplied by ASTRA Pharmaceutics, Rijswijk, The 
Netherlands. The inhalers contained budesonide with 
200 ,ug puff ~ ’ ) or placebo. Four puffs were inhaled 
two times a day via a spacer device (Nebuhaler). 
STATISTICS 
Diary card parameters and PEFR values were 
averaged over the 2 week run-in period, and over the 
last 2 weeks in the two treatment periods. The 
Wilcoxon test for paired differences was used on lung 
function data, log PC,,, mean PEFR and symptom 
scores. Five percent was taken as the level of 
significance. Data are expressed as mean & SEM. 
Results 
Of the 16 patients who started the study, 12 
patients provided complete data for analysis. Patient 
characteristics are given in Table 1. Two patients 
were withdrawn from the study because of non- 
compliance, both during placebo treatment. One 
patient was withdrawn from the trial after a viral 
illness and subsequent exacerbation of airways infec- 
tion with Pseudomonas aeruginosa during treatment 
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Table 2 Effects of treatment with placebo and budesonide on lung function, symptom scores, 
daily peak flow expiratory rate and &agonist use (puffs day- ‘) in 12 adult patients with cystic 
fibrosis (mean values). P-values denote significant differences between values after placebo and 
values after budesonide. Baseline data represent values after the run-in period 
Spirometry values 
FEV, (1) 
FVC (1) 
MEFso (1 min - ‘) 
Diary card scores (O-3) 
Baseline Placebo 
2.3 2.2 
3.5 3.3 
1.7 1.7 
Budesonide P-value 
2.3 NS 
3.6 NS 
1.9 NS 
Dyspnoea at rest 0.47 0.54 
Dyspnoea on exercise 0.73 0.97 
Cough 1.19 1.20 
Sputum production 2.2 2.3 
Morning PEFR (1 min ‘) 433 416 
Evening PEFR (1 min ‘) 449 442 
&agonist use 1.2 1.2 
0.38 PCO.05 
0.98 NS 
1.14 P-=0.05 
2.3 NS 
421 NS 
443 NS 
1.1 NS 
with budesonide, whereas the fourth patient was 
withdrawn after a trauma (broken leg). The airways 
were colonized (2 three sputum cultures) with 
Pseudomonas aeruginosa in eight patients (patient no. 
1, 2, 4, 6, 7, 9, 11, 12), with Haemophilus influenza 
and Staphylococcus aureus in one patient (no. 5), with 
S. aureus alone in one patient (no. 8), whereas the 
remaining two patients (no. 3, 10) did not have 
bacterial colonization of their airways at the time of 
the study. Three patients (no. 8, 11, 12) used prophy- 
lactic antibiotics throughout the study. No patients 
started or stopped antibiotics during the trial. 
The results of baseline spirometry before and after 
the 2 weeks run-in period were comparable within a 
5% range. Also, the PC,, histamine levels showed 
good reproducibility: Log PC,, values were 
0.22 & 0.15 before, and 0.22 * 0.18 at the end of the 
run-in period. During placebo treatment, no sign&- 
cant changes occurred in any of the spirometric 
values (Table 2). Also, mean Log PC,, histamine 
after placebo was not significantly different from 
baseline. 
After 6 weeks treatment with budesonide, small, 
but not significant, changes were observed in FEV, 
and FVC (Table 2). None of the patients showed an 
increase in baseline FEV, (1) of > 15% after budes- 
onide. The mean Log PC,, histamine increased after 
budesonide from 0.22 to 0.50 mg ml ~ ’ (PcO.01). 
The geometric mean PC,, histamine increased from 
1.6 to 3.2 mg ml- ‘, the difference being small but 
statistically significant. Seven patients showed at least 
one doubling dose increase in PC,, histamine (Fig. 
1). Of these seven patients, two were allergic. 
32 
16 
8 
0.25 
0.125 
Baseline Budesonide 
Fig. 1 Individual data (0) and mean values (-) of PC 
histamine levels (mg ml ‘), before and after 6 weeks of 
treatment with 1600 pug day 1 budesonide in 12 adult CF 
patients. 
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No correlation was found between the improvement 
in PC,, and the change in FEV,, or with baseline 
FEV,. Daily symptom scores, PEFR measurements 
and the use of &agonists were collected from the 
diary cards. The mean diurnal variation of PEFR 
was 3.9% (range 0.3-8.9%) and did not change dur- 
ing treatment periods. None of the individual 
patients showed a diurnal variation of PEFR > 10%. 
A small improvement in the scores for dyspnoea at 
rest (P=O.O2) and cough (P=O.O3) could be observed 
after budesonide treatment in comparison with 
placebo (Table 2). The other parameters showed no 
significant differences between the two treatment 
periods. No significant differences were seen in the 
budesonide period when compared to placebo 
period, with respect to bacterial colonization, need 
for hospital admission and antibiotic therapy. No 
side effects were reported by the patients. Four 
patients were arbitrarily considered allergic. These 
four patients showed positive RAST tests to two or 
more inhalational allergens. These positive RAST 
tests were Aspergillus fumigatus (2) tree pollen (2) 
grass pollen (3) and house dust mite (2). No eosino- 
philia was present in the studied patients. No patient 
suffered from clinical allergy. The results of all tests 
were not significantly different between allergic and 
non-allergic subjects. 
Discussion 
The results of this study indicate that treatment 
with inhaled corticosteroids decreases bronchial 
hyperresponsiveness in adult patients with CF. This 
is the first study showing that the severity of 
bronchial hyperresponsiveness in CF patients can 
be decreased with anti-inflammatory therapy. In 
patients with asthma, long term treatment with 
inhaled corticosteroids showed clear improvement in 
bronchial hyperresponsiveness, lung function and 
clinical symptom scores (11,12,19,20). The efficacy of 
inhaled corticosteroids is controversial in chronic 
obstructive pulmonary disease (COPD). Several 
studies have shown no significant improvement in 
FEV, or bronchial responsiveness to histamine, in an 
overall population of COPD patients treated with 
inhaled corticosteroids (1618). In non-CF patients 
with bronchiectasis, lung function, cough and 
sputum production improved significantly after daily 
inhalation of 1500,~~g beclomethason over 6 weeks 
(21). Treatment with inhaled sodium cromoglycate in 
CF patients showed no beneficial effects on symp- 
toms, pulmonary function tests or methacholine 
responsiveness (22). Controlled trials using inhaled 
corticosteroids in CF patients have not yet been 
reported. A retrospective study showed some 
beneficial effects on lung function of treatment with 
inhaled steroids, as adjunct to antibiotics in selected 
CF patients during an exacerbation of airways 
infection (23). We performed a double-blind, 
placebo-controlled, cross-over trial with high dose 
budesonide and found a beneficial effect on bronchial 
hyperresponsiveness. 
The decrease in PC,, histamine was not ac- 
companied by an increase in spirometeric values. It 
is possible that the number of patients limited the 
statistical power of the trial to detect small changes. 
Daily symptom scores showed small, but significant, 
improvements in dyspnoea at rest, and in coughing. 
Seven of the 12 patients showed at least one doubling 
dose increase in PC,, histamine. The improvement 
in PC,, could not be attributed to improvement in 
bronchial calibre, because no correlation existed 
between the change in PC,, and the change in FEV,, 
if present. Although the observed beneficial effects of 
an inhaled corticosteroid on this group of adult CF 
patients were small, the results are encouraging. 
Whether a longer observation period than 6 weeks, 
and doses of budesonide above 1600 pg day - ’ would 
provide stronger beneficial effects on lung function, 
remains to be determined. 
The attenuation of bronchial hyperresponsiveness 
without concomitant change in airway calibre, might 
reflect a decrease in epithelial permeability and/or 
the presence of inflammatory cells and mediators. 
Others have shown that in patients with CF, 
bronchial hyperresponsiveness is an unfavourable 
prognostic finding, associated with more rapid 
pulmonary deterioration (2). In the CF lung, elevated 
levels of neutrophil proteases, such as elastase, 
tumour necrosis factor and Interleukin-8 suggest a 
self-perpetuating inflammatory process on the 
bronchial surface (24,25). Several data suggest the 
existence of an excessive inflammatory immune 
response in the lungs of CF patients (26). In this view, 
the use of the non-steroidal, anti-inflammatory drug 
ibuprofen was investigated in a rat model of chronic 
pseudomonas endobronchial infection. Ibuprofen 
significantly decreased the extent of the inflammatory 
response without increasing the pulmonary burden of 
bacteria (27). Following also the concept of hyper- 
inflammation, several trials of immunosuppressive 
therapy using oral corticosteroids have been per- 
formed in CF patients. A short term trial of 0.5 mg 
kg - ’ prednisolone daily over 3 weeks in 15 CF 
patients with severe airflow obstruction, showed no 
significant improvement in spirometry or clinical 
condition (28). However, in a long term controlled 
study with 2 mg kg - ’ prednisolone on alternate 
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days, significant beneficial effects (better lung fimc- 
tion, less hospital admissions) were seen in a group of 
45 children with CF, aged 1-12 years (29). These 12. 
results suggest that the corticosteroid therapy had 
modulated the excessive immune response. Unfortu- 
nately, longer follow-up of CF patients treated with 
oral corticosteroids showed a variety of important 
and unacceptable adverse effects, such as substantial 13. 
growth retardation, early cataract formation and 
glucose intolerance (30,3 1). Therefore, at present, 
chronic oral corticosteroid treatment cannot be 
recommended. 14 
In summary, there is increasing evidence to suggest l5 
that excessive inflammatory responses contribute, at 
least in part, to the pulmonary damage that charac- 
terizes CF. In this study of adult CF patients, we 16 
found that daily inhalation of 16OOpg budesonide 
for 6 weeks induced a small, but significant, improve- l7 
ment in bronchial responsiveness to histamine, and 
symptoms of cough and dyspnoea. Longer obser- 
vations are needed to establish whether inhaled 
corticosteroids improve the long term outcome 18. 
of CF. 
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